Showing 6591-6600 of 10001 results for "".
- BrightGuard Installs Free Sunscreen Dispensers at New York City Public Pools and Beacheshttps://practicaldermatology.com/news/brightguard-installs-free-sunscreen-dispensers-at-new-york-city-public-pools-and-beaches/2457708/Through its ongoing partnership with non-profit sponsor and donor IMPACT Melanoma and sunscreen provider Coppertone, BrightGuard has installed 134 sunscreen dispensers throughout New York City (NYC) public pools and beaches. BrightGuard—the first aut
- FDA Approves Dermira's Qbrexza Cloth to Treat Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/fda-approves-delmiras-qbrexza-cloth-to-treat-primary-axillary-hyperhidrosis/2457709/The FDA has approved Qbrexza™ (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza is applied directly to the skin and is designed to block sweat production by inhib
- Dermatology Authority Adds Credentialing and Licensing Support Serviceshttps://practicaldermatology.com/news/dermatology-authority-adds-credentialing-and-licensing-support-services/2457711/Dermatology Authority has added credentialing and licensing to their list of support services. The requirements for licensing and credentialing differ from city to city, state to state, and procedure to procedure. Dermatology Authority keeps tab
- UVBioTek Launches POLY Go Portable LED Light Therapyhttps://practicaldermatology.com/news/uvbiotek-launches-poly-go-portable-led-light-therapy/2457714/UVBioTek has launched a new line of hand-held LED therapy products that support their newest brand, POLY LED Light Therapy. The mobile hand-held products, named “POLY Go”, use multiple wavelengths that are clinically proven to cater to those with acne, fine-
- CBD Naturals to Introduce New Skincare Linehttps://practicaldermatology.com/news/cbd-naturals-to-introduce-new-skincare-line/2457717/Delivering natural beauty from the inside out, CBD Naturals® will introduce Floré™, a prestigious new line of skincare products, at the International Cannabis Business Conference in Vancouver on June 25. Floré™ incorporates cutting-edge ingredient formulas that
- FDA-Approved Label Update: Cosentyx Inhibits Progression of Joint Structural Damage in PsAhttps://practicaldermatology.com/news/fda-approved-label-update-cosentyx-inhibits-progression-of-joint-structural-damage-in-psa/2457718/The US FDA has approved a label update for Cosentyx® (secukinumab) from Novartis, including data that show the treatment significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA). The data will be a
- eRelevance Launches Suite of Services to Support Lead Conversionhttps://practicaldermatology.com/news/erelevance-launches-suite-of-services-to-support-lead-conversion/2457726/eRelevance Corporation has launched a suite of tech-powered services to help
- Restoration Robotics Launches Continuing Education Master Class for ARTAS Systemhttps://practicaldermatology.com/news/restoration-robotics-launches-continuing-education-master-class-for-artas-system/2457729/Restoration Robotics, Inc. is launching a continuing education Master Class Series for its ARTAS® Robotic Hair Restoration System to train physicians on best practices and the most up-to-date techniques for the technology. The Master Class Series will enable users to provide exceptional
- InMode: New EmbraceRF Solution Introduces Subdermal Adipose Remodelinghttps://practicaldermatology.com/news/inmode-new-embracerf-solution-introduces-subnormal-adipose-remodeling/2457733/Introducing the concept of Subdermal Adipose Remodeling, InMode Aesthetic Solutions is launching EmbraceRF to target the neck and face through a powerful combination of
- Opdivo Data: Superior Recurrence-Free Survival Versus Ipilimumabhttps://practicaldermatology.com/news/opdivo-data-superior-recurrence-free-survival-versus-ipilimumab/2457734/Updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab, Bristol-Myers Squibb Company) versus Yervoy (ipilimumab, Bristol-Myers Squibb Company) in patients with stage IIIB/C or stage IV melanoma who are at high ri